CA-G2-RISK-SOLUTIONS
27.8.2024 15:08:33 CEST | Business Wire | Press release
G2 Risk Solutions (G2RS), the global leader in risk and compliance business intelligence, today celebrates the release of the API version of its cornerstone product, advancing its vision to simplify and optimize merchant risk management for acquiring banks and payments facilitators. Global Onboarding, an AI-powered merchant onboarding solution, helps users safely onboard new merchants quickly with highly accurate predictive risk assessments.
One solution to manage it all
Global Onboarding is the final building block in a unified solution that integrates onboarding seamlessly with G2RS monitoring products, Persistent Merchant Monitoring and Transaction Laundering Detection. For the first time, risk managers have the ability within a single platform to underwrite merchants, approve them intelligently at scale, and then usher the flow of approved merchants in and out of activities that continuously monitor for a wide variety of illegal and/or violative conduct.
“We’re thrilled to be the first to deliver an integrated solution based on our Merchant Map® and enhanced AI,” said Brian Longe, G2RS chief executive officer. “Our customers need to operate quickly and accurately to capture new merchant opportunities while also minimizing merchant portfolio risk. Speed is money, and our solution finally lets them scale up in a safe, smart way.”
Innovation to match evolution
As the e-commerce landscape expands with new online merchants and digital payment options, competition has increased. At the same time, regulations have gotten increasingly complex and punitive, and bad actors have become more sophisticated. Companies need innovation and agility to stay ahead in this ecosystem. Effective merchant onboarding is a critical step in the efficient setup of merchant clients for secure digital payment acceptance while avoiding exposure to fraud, card service rule infractions, and regulatory fines.
"The expanding e-commerce landscape presents exciting opportunities and significant challenges for the payments industry," said Rochelle Blease, G2RS president of merchant risk solutions. "Global Onboarding empowers financial institutions and other payments providers to navigate this dynamic environment confidently, acting swiftly on new business opportunities while minimizing exposure to illegal activity and non-compliance."
Combining the industry’s best resources
Global Onboarding incorporates advanced proprietary technology to enable rapid, confident merchant onboarding. The solution includes robust G2RS risk mitigation and business enablement capabilities that are unique within the payments industry, including:
- Merchant Map®, a proprietary, industry-exclusive merchant behavior database built over 20+ years with billions of data points, all validated by G2RS expert analysts.
- Compass Score®, a comprehensive, AI-driven score that predicts the risk of problematic merchant activity during the next 12 months. The scoring models synthesize data from the Merchant Map and additional data sources, including watchlists and sanctions registries, consumer ratings and adverse media, and risk-based insights for content compliance and operational risk.
- Merchant lifecycle risk management, a comprehensive approach covering risk from underwriting and onboarding to ongoing monitoring and transaction laundering detection, with re-underwriting as needed for audits or investigations.
"Our global customers need tools that keep pace with the increasing complexity and growth of the industry,” said Gavin Andrews, G2RS director of product management. “The AI-powered insights, comprehensive risk evaluations, and automation-ready workflows in Global Onboarding address the critical needs for efficiency, accuracy, and smarter decision-making when onboarding merchants. This is fintech that helps payments providers more confidently scale their operations.”
To learn more, visit g2risksolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827954388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom